Organization | SCOPE International AG

SCOPE International AG Report issue

For profit Phase 1

Founded: Mannheim Germany (2000)

Organization Overview

First Clinical Trial

2017

NCT03058224

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

SCOPE International AG

Active Ingredients

Drugs in Phase 1 Trials (1)

ob-002 (1 trial)

Drugs in Other Trials (2)

acetaminophen (tylenol) (1 trial)

polyclonal avian immunoglobulin igy containing specific igy against e. coli f18ab and s. typhimurium (1 trial)

Indications

Overview

Highest Phase: Phase 1
# of Trials: 2
# of Trial APIs: 3